Janus Global Life Sciences Fund (JAGLX)

Sector Experts Seeking Growth and Innovation in Health Care

SHARE CLASS

FUND FACTS (JAGLX)

Inception Date12/31/1998
NAV (As of 2/5/16 )$43.34
Total Net Assets (As of 12/31/15)$4.68B
Annual Expense Ratio
(As of fiscal year end 9/30/15)
GROSS 0.95%
NET 0.95%

Performance (As of 12/31/15)
1 Year8.24%
3 Year31.48%
5 Year24.88%
10 Year13.50%
Morningstar (As of 1/31/16)
CategoryHealth
Overall Rating™
(Based on risk-adjusted returns)

View All Ratings

125 Funds Rated
Equity
Style Box

Returns quoted are past performance and do not guarantee future results; current performance may be lower or higher. Investment returns and principal value will vary; there may be a gain or loss when shares are sold. For the most recent month-end performance click here.

Returns greater than one year are annualized.

Straight Talk

Quarterly Commentary - Q4 2015

EXECUTIVE SUMMARY

Quarterly returns for the health care sector were positive and outperformed broader global markets.

The Fund underperformed its primary benchmark, due largely to our holdings in the pharmaceutical subsector.

We believe innovation and increased merger and acquisition activity are creating a favorable backdrop for the sector, though political rhetoric around drug pricing will be a source of volatility in 2016.

FUND MANAGEMENT

Andy Acker, CFA

Andy Acker, CFA

Fund Manager since 2007
Industry since 1996

Ethan Lovell

Ethan Lovell

Fund Manager since 2016
Industry since 1994